395 related articles for article (PubMed ID: 27256987)
21. Spectral-Domain OCT Analyses of Macular Changes After Ranibizumab Therapy for Type 1 Retinopathy of Prematurity.
Erol MK; Coban DT; Özdemir Ö; Tunay ZÖ; Bilgin AB; Dogan B
J Pediatr Ophthalmol Strabismus; 2015; 52(3):152-8. PubMed ID: 25859685
[TBL] [Abstract][Full Text] [Related]
22. Ranibizumab injection and laser photocoagulation to treat type 1 retinopathy of prematurity after 40 weeks post menstrual age: a retrospective case series study.
Lyu J; Zhang Q; Chen C; Xu Y; Ji X; Zhao P
BMC Ophthalmol; 2019 Feb; 19(1):60. PubMed ID: 30808338
[TBL] [Abstract][Full Text] [Related]
23. Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial.
Geloneck MM; Chuang AZ; Clark WL; Hunt MG; Norman AA; Packwood EA; Tawansy KA; Mintz-Hittner HA;
JAMA Ophthalmol; 2014 Nov; 132(11):1327-33. PubMed ID: 25103848
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab for retinopathy of prematurity as first line or rescue therapy with focal laser treatment. A case series.
Dani C; Frosini S; Fortunato P; Bertini G; Pratesi S; Pollazzi L; Caputo R; La Torre A
J Matern Fetal Neonatal Med; 2012 Nov; 25(11):2194-7. PubMed ID: 22506618
[TBL] [Abstract][Full Text] [Related]
25. Comparison of post-treatment recurrence between ranibizumab injection and laser photocoagulation for type 1 retinopathy of prematurity.
Cao JK; Han T; Tang HY; Zhang S; Wang ZH; Feng ZC; Li QP
BMC Ophthalmol; 2023 Apr; 23(1):137. PubMed ID: 37016343
[TBL] [Abstract][Full Text] [Related]
26. Outcomes and prognostic factors for aggressive posterior retinopathy of prematurity following initial treatment with intravitreal ranibizumab.
Tong Q; Yin H; Zhao M; Li X; Yu W
BMC Ophthalmol; 2018 Jun; 18(1):150. PubMed ID: 29940900
[TBL] [Abstract][Full Text] [Related]
27. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
[TBL] [Abstract][Full Text] [Related]
28. Ranibizumab Injection as Primary Treatment in Patients with Retinopathy of Prematurity: Anatomic Outcomes and Influencing Factors.
Huang Q; Zhang Q; Fei P; Xu Y; Lyu J; Ji X; Peng J; Li YA; Zhao P
Ophthalmology; 2017 Aug; 124(8):1156-1164. PubMed ID: 28412066
[TBL] [Abstract][Full Text] [Related]
29. FLUORESCEIN ANGIOGRAPHIC EVALUATION OF PERIPHERAL RETINAL VASCULATURE AFTER PRIMARY INTRAVITREAL RANIBIZUMAB FOR RETINOPATHY OF PREMATURITY.
Harper CA; Wright LM; Young RC; Read SP; Chang EY
Retina; 2019 Apr; 39(4):700-705. PubMed ID: 29300248
[TBL] [Abstract][Full Text] [Related]
30. Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection.
Milani AE; Arasteh A; Saeedi-Maleki Z; Niyousha MR; Sahebazamani MA; Brumandpur F
BMC Ophthalmol; 2024 Jun; 24(1):265. PubMed ID: 38907228
[TBL] [Abstract][Full Text] [Related]
31. SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.
Jin E; Yin H; Li X; Zhao M
Retina; 2018 Aug; 38(8):1595-1604. PubMed ID: 28699927
[TBL] [Abstract][Full Text] [Related]
32. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
Kim J; Kim SJ; Chang YS; Park WS
Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
[TBL] [Abstract][Full Text] [Related]
33. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
Sukgen EA; Koçluk Y
Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
[TBL] [Abstract][Full Text] [Related]
34. Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity.
Gangwe AB; Agrawal D; Gangrade AK; Parchand SM; Agrawal D; Azad RV
Indian J Ophthalmol; 2021 Aug; 69(8):2171-2176. PubMed ID: 34304203
[TBL] [Abstract][Full Text] [Related]
35. Comparison of intravitreal bevacizumab monotherapy and combined laser photocoagulation and intravitreal bevacizumab therapy in the same session in the treatment of aggressive retinopathy of prematurity.
Sabancı Ş; Küçük MF; Süren E; Erol MK
Int Ophthalmol; 2024 Jul; 44(1):305. PubMed ID: 38954120
[TBL] [Abstract][Full Text] [Related]
36. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
[TBL] [Abstract][Full Text] [Related]
37. Smouldering retinopathy of prematurity: a case treated by multiple antivascular endothelial growth factor therapy.
Balakrishnan D; Ambiya V; Jalali S; Rani PK
BMJ Case Rep; 2016 Aug; 2016():. PubMed ID: 27571916
[TBL] [Abstract][Full Text] [Related]
38. Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab.
Snyder LL; Garcia-Gonzalez JM; Shapiro MJ; Blair MP
Ophthalmic Surg Lasers Imaging Retina; 2016 Mar; 47(3):280-3. PubMed ID: 26985803
[TBL] [Abstract][Full Text] [Related]
39. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
[TBL] [Abstract][Full Text] [Related]
40. Combine intravitreal bevacizumab injection with laser treatment for aggressive posterior retinopathy of prematurity (AP-ROP).
Wutthiworawong B; Thitiratsanont U; Saovaprut C; Subhangkasen I; Geyuraphun B; Ampornprut A; Phumongkutchai J; Tephusdinnaayuthaya S
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S15-21. PubMed ID: 22043749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]